Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miles Medrano

Gastroenterology Atlantis, FL Medical Doctor

NPI 1366487514 CMS profile 198167

5401 S Congress Ave, #211, Atlantis, FL 33462

Open in the dashboard

General payments

$6,349

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$11,329

4 holdings reported · through program year 2025

Through program year 2025, Miles Medrano of Atlantis, FL is reported in the CMS Open Payments database as having received $6,349 across 363 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $11,329 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,361 59
2024 General $998 46
2023 General $1,031 54
2022 General $662 40
2021 General $823 57
2020 General $419 28
2019 General $1,055 79
2024 Ownership $5,340 1
2023 Ownership $5,340 1
2022 Ownership $335 1
2021 Ownership $313 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miles Medrano
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Miles Medrano were reported at $1,361. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Miles Medrano Gastroenterology median Middle half National median
2019 $1,055 $417 $126–$1,100 $163
2020 $419 $224 $74–$624 $114
2021 $823 $352 $106–$1,054 $132
2022 $662 $448 $129–$1,270 $149
2023 $1,031 $533 $150–$1,390 $160
2024 $998 $605 $160–$1,606 $164
2025 $1,361 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,814 111 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $767 48 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $586 27 payments
  4. Janssen Biotech, Inc. $492 28 payments
  5. Celgene Corporation $307 18 payments
  6. Gilead Sciences, Inc. $282 14 payments
  7. Intercept Pharmaceuticals, Inc. $238 13 payments
  8. Braintree Laboratories, Inc. $205 21 payments
  9. QOL Medical, LLC $200 12 payments
  10. Madrigal Pharmaceuticals $176 6 payments
  11. Other $1,282 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,189 345 payments
  2. Education $161 18 payments
Products named General payments · program years 2019–2025
  1. LINZESS $703 48 payments
  2. XIFAXAN $683 42 payments
  3. CREON $481 31 payments
  4. RINVOQ $447 21 payments
  5. STELARA $365 22 payments
  6. HUMIRA $316 21 payments
  7. ENTYVIO $293 12 payments
  8. ZEPOSIA $287 17 payments
  9. VIBERZI $259 15 payments
  10. SKYRIZI $223 9 payments
  11. Other $3,378 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,824

Median for Gastroenterology: 569

Drug cost

$252,613

Median for Gastroenterology: $104,976

Branded share of claims

26.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ocaliva Obeticholic Acid Brand 13 $122,601
Linzess Linaclotide Brand 69 $60,838
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 232 $16,059
Mesalamine Generic 32 $7,027
Dicyclomine Hcl Generic 298 $6,279
Cholestyramine Cholestyramine (With Sugar) Brand 67 $4,946
Omeprazole Generic 398 $4,736
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 29 $4,706
Dexlansoprazole Dr Dexlansoprazole Brand 19 $4,405
Ursodiol Generic 31 $3,904

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$62,611

Medicare's payments for the services billed

Medicare patients

280

Average age 75

Services billed

554

155 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 52%
Ischemic heart disease 39%
Diabetes 32%
Chronic kidney disease 25%
Depression 23%
Osteoporosis 22%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $101
$101 — —
ZEPOSIA
  • Celgene Corporation $99
$99 — —
STELARA
  • Janssen Biotech, Inc. $98
$98 — —
SKYRIZI
  • AbbVie, Inc. $95
$95 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record